Bristol-Myers Squibb Co. v. Superior Court of California
Justia Summary
Plaintiffs, most of whom are not California residents, sued BMS in California state court, alleging that the pharmaceutical company’s drug Plavix had damaged their health. BMS is incorporated in Delaware and headquartered in New York; it maintains substantial operations in New York and New Jersey. BMS engages in business activities in California and sells Plavix there, but did not develop, create a marketing strategy for, manufacture, label, package, or work on the regulatory approval for Plavix in California. The nonresident plaintiffs did not allege that they obtained Plavix from a California source, that they were injured in California, or that they were treated for their injuries in California. The California Superior Court found that it had general jurisdiction. The state supreme court found that BMS’s “wide-ranging” contacts with the state supported a finding of specific jurisdiction over the nonresident plaintiffs’ claims. The Supreme Court reversed. For general jurisdiction, the “paradigm forum” is an “individual’s domicile,” or, for corporations, “an equivalent place, one in which the corporation is fairly regarded as at home.” Specific jurisdiction requires the suit to “aris[e] out of or relat[e] to the defendant’s contacts with the forum.” The primary concern is the burden on the defendant. The California Supreme Court found specific jurisdiction without identifying any adequate link between the state and the nonresidents’ claims. It is not relevant that BMS conducted research in California on matters unrelated to Plavix. BMS’s decision to contract with a California company to distribute Plavix nationally does not provide a sufficient basis for personal jurisdiction.
About Author
